We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Gracell Biotechnologies Inc | NASDAQ:GRCL | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.25 | 10.25 | 10.00 | 0 | 01:00:00 |
From May 2022 to May 2024
By Sabela Ojea
Shares of Gracell Biotechnologies Inc. jumped Friday after the company said the U.S. Food and Drug Administration approved its investigational new drug application to treat a type of cancer targeting plasma cells.
At 12:35 p.m. ET, shares were up 8% at $2.30.
The China-based clinical-stage biopharmaceutical company said it can now initiate a Phase 1b/2 clinical trial for its therapeutic candidate FasTCAR-T GC012F, which targets relapsed or refractory multiple myeloma.
Relapsed or refractory multiple myeloma occurs when cancer of the plasma cells returns or doesn't respond to treatment.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
February 03, 2023 12:50 ET (17:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gracell Biotechnologies Chart |
1 Month Gracell Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
